Interleukin-23 receptor polymorphism as a risk factor for oral cancer susceptibility

Head and Neck

Volumn 34, Issue 4, 2012, Pages 551-556

  Chien, Ming Hsien ^a,b   Hsin, Chung Han ^c,d   Shih Shen Chou, Lin ^c,d   Chung, Tsung Te ^d,e   Lin, Chien Huang ^b   Weng, Meng Shih ^f   Chou, Ming Yung ^c,d   Chen, Mu Kuan ^d,g   Yang, Shun Fa ^c,d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^f FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^g CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

genetic polymorphism; IL 23; IL 23 receptor; oral cancer

Indexed keywords

INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR;

ADULT; ALLELE; ARTICLE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; HOMOZYGOSITY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGE DISTRIBUTION; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DNA, NEOPLASM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; MULTIVARIATE ANALYSIS; ODDS RATIO; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROGNOSIS; RECEPTORS, INTERLEUKIN; RETROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; TAIWAN;

EID: 84858077257     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21779     Document Type: Article

References (40)

1. Yang SF, Yang WE, Chang HR, Chu SC, Hsieh YS,. Luteolin induces apoptosis in oral squamous cancer cells. J Dent Res 2008; 87: 401-406.
2. Lo WY, Tsai MH, Tsai Y, et al. Identification of over-expressed proteins in oral squamous cell carcinoma (OSCC) patients by clinical proteomic analysis. Clin Chim Acta 2007; 376: 101-107. (Pubitemid 44880973)
3. Funk GF, Karnell LH, Robinson RA, Zhen WK, Trask DK, Hoffman HT,. Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report. Head Neck 2002; 24: 165-180. (Pubitemid 34111514)
4. Muir C, Weiland L,. Upper aerodigestive tract cancers. Cancer 1995; 75 (1 Suppl): 147-153.
5. Lo WL, Kao SY, Chi LY, Wong YK, Chang RC,. Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival. J Oral Maxillofac Surg 2003; 61: 751-758. (Pubitemid 36754024)
6. Chen YJ, Chang JT, Liao CT, et al. Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. Cancer Sci 2008; 99: 1507-1514.
7. Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, Tsai CC,. Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med 1995; 24: 450-453.
8. Biolchini F, Pollastri G, Figurelli S, Chiarini L,. Carcinogen metabolism, DNA damage repair and oral head and neck squamocellular carcinoma (HNSCC). A review. Minerva Stomatol 2005; 54: 405-414.
9. Nagaraj NS, Beckers S, Mensah JK, Waigel S, Vigneswaran N, Zacharias W,. Cigarette smoke condensate induces cytochromes P450 and aldo-keto reductases in oral cancer cells. Toxicol Lett 2006; 165: 182-194. (Pubitemid 44202254)
10. Ramachandran S, Ramadas K, Hariharan R, Rejnish Kumar R, Radhakrishna Pillai M,. Single nucleotide polymorphisms of DNA repair genes XRCC1 and XPD and its molecular mapping in Indian oral cancer. Oral Oncol 2006; 42: 350-362.
11. Chen MK, Chiou HL, Su SC, et al. The association between hypoxia inducible factor-1alpha gene polymorphisms and increased susceptibility to oral cancer. Oral Oncol 2009; 45: e222-226.
12. Chen MK, Tsai HT, Chung TT, et al. Glutathione S-transferase P1 and alpha gene variants; role in susceptibility and tumor size development of oral cancer. Head Neck 2010; 32: 1079-1087.
13. Teng YH, Liu TH, Tseng HC, et al. Contribution of genetic polymorphisms of stromal cell-derived factor-1 and its receptor, CXCR4, to the susceptibility and clinicopathologic development of oral cancer. Head Neck 2009; 31: 1282-1288.
14. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13: 715-725.
15. Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002; 168: 5699-5708. (Pubitemid 34556153)
16. Becher B, Durell BG, Noelle RJ,. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest 2002; 110: 493-497. (Pubitemid 34919703)
17. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421: 744-748. (Pubitemid 36227625)
18. Ghilardi N, Kljavin N, Chen Q, Lucas S, Gurney AL, De Sauvage FJ,. Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice. J Immunol 2004; 172: 2827-2833. (Pubitemid 38263667)
19. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-240. (Pubitemid 40189432)
20. Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003; 198: 1951-1957. (Pubitemid 38032126)
21. Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature 2006; 442: 461-465. (Pubitemid 44264796)
22. Langowski JL, Kastelein RA, Oft M,. Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol 2007; 28: 207-212. (Pubitemid 46654872)
23. Capon F, Di Meglio P, Szaub J, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007; 122: 201-206. (Pubitemid 47241785)
24. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-1463. (Pubitemid 44871953)
25. Huber AK, Jacobson EM, Jazdzewski K, Concepcion ES, Tomer Y,. Interleukin (IL)-23 receptor is a major susceptibility gene for Graves' ophthalmopathy: the IL-23/T-helper 17 axis extends to thyroid autoimmunity. J Clin Endocrinol Metab 2008; 93: 1077-1081. (Pubitemid 351398595)
26. Kim TH, Hong JM, Oh B, et al. Association of polymorphisms in the interleukin 23 receptor gene with osteonecrosis of femoral head in Korean population. Exp Mol Med 2008; 40: 418-426.
27. Illes Z, Safrany E, Peterfalvi A, et al. 3′UTR C2370A allele of the IL-23 receptor gene is associated with relapsing-remitting multiple sclerosis. Neurosci Lett 2008; 431: 36-38.
28. Chen J, Lu Y, Zhang H, et al. A nonsynonymous polymorphism in IL23R gene is associated with risk of gastric cancer in a Chinese population. Mol Carcinog 2010; 49: 862-868.
29. Zhang Z, Zhou B, Zhang J, et al. Association of interleukin-23 receptor gene polymorphisms with risk of ovarian cancer. Cancer Genet Cytogenet 2010; 196: 146-152.
30. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL,. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278: 1910-1914. (Pubitemid 36801431)
31. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-1132. (Pubitemid 41541790)
32. Dunn GP, Old LJ, Schreiber RD,. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329-360. (Pubitemid 38680426)
33. Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101: 2620-2627. (Pubitemid 36857622)
34. Jovanovic DV, Martel-Pelletier J, Di Battista JA, et al. Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages: a possible role in rheumatoid arthritis. Arthritis Rheum 2000; 43: 1134-1144. (Pubitemid 30368194)
35. Garley M, Jablonska E, Grabowska SZ, Piotrowski L,. IL-17 family cytokines in neutrophils of patients with oral epithelial squamous cell carcinoma. Neoplasma 2009; 56: 96-100.
36. Yao JG, Gao LB, Liu YG, Li J, Pang GF,. Genetic variation in interleukin-10 gene and risk of oral cancer. Clin Chim Acta 2008; 388: 84-88. (Pubitemid 350266574)
37. Vairaktaris E, Yannopoulos A, Vassiliou S, et al. Strong association of interleukin-4 (-590 C/T) polymorphism with increased risk for oral squamous cell carcinoma in Europeans. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104: 796-802.
38. Vairaktaris E, Yapijakis C, Serefoglou Z, et al. Gene expression polymorphisms of interleukins-1 beta, -4, -6, -8, -10, and tumor necrosis factors-alpha, -beta: regression analysis of their effect upon oral squamous cell carcinoma. J Cancer Res Clin Oncol 2008; 134: 821-832.
39. Chen Y, Zhou B, Peng Y, et al. Interleukin-23 receptor gene polymorphisms is associated with dilated cardiomyopathy in Chinese Han population. Tissue Antigens 2009; 73: 330-334.
40. Faragó B, Magyari L, Sáfrány E, et al. Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemic sclerosis. Ann Rheum Dis 2008; 67: 248-250. (Pubitemid 351183317)